Last year, Baxter’s BioPharma Solutions business (www.baxterbiopharmasolutions.com) expanded its cytotoxic contract manufacturing capacity to increase support of early-phase oncology sterile drug formulation through commercial scale-up, introduction, and lifecycle management. In need of a capacity extension, Baxter replaced a vial-filling machine with a highly automated filling line including a closed Restricted Access Barrier System (cRABS) dedicated for aseptic manufacturing of cytotoxics at its manufacturing facility in Halle (Westfalen), Germany.
McNeil Consumer Healthcare is recalling one product lot of Tylenol 8-Hour caplets 50 count bottles to the retail level. McNeil is taking this action following a small number of complaints of a musty or moldy odor. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Covance Inc. expands its biotechnology offerings into North America with the opening of a biotechnology services facility on its Greenfield campus in Indiana. This facility will use the expertise developed and offered by Covance in the United Kingdom for more than 20 years.
Dymax Corp. has expanded their online presence with several new business-to-business social networking initiatives. On their Web site, visitors can find an informative blog where they can read questions and answers posted by Dymax’s adhesive and equipment experts.
Included in the Dymax blog are educational posts on various topics, such as curing equipment, safety, and adhesives and coatings for a wide array of applications in the medical, electronic, and structural industries.
To reduce the chance for mixup, FDA has approved changing the name of the heartburn drug dexlansoprazole from Kapidex to Dexilant. This new name aims to avoid confusion with two other medications, Casodex and Kadian. Takeda Pharmaceuticals North America Inc. will begin marketing the drug under the new name in late April 2010.
A former scrub technician has been sentenced to 30 years' federal imprisonment for crimes including tampering with syringes and exposing patients to blood-borne pathogens. Yesterday in Colorado, Kristen Parker was sentenced by U.S. District Court Judge Robert E. Blackburn to serve 360 months (30 years) in federal prison, followed by 3 years of supervised release.